Appili Therapeutics Inc. (APLI.TO)
Toronto · CAD · Healthcare · Biotechnology
CA$0.005 (-50.00%) as of
Key statistics
- Market cap
- 661.83k
- Forward P/E
- -0.12
- EPS (TTM)
- -0.0400
- Dividend yield
- 0.00%
- 52-week range
- 0.0050 – 0.0300
- Beta
- 0.14
- Revenue (TTM)
- 362.07k
- Profit margin
- 0.00%
- Volume
- 117.00k
About Appili Therapeutics Inc.
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections. It also develops ATI-1801, a topical formulation of paromomycin in a Phase III trial for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine in preclinical trials for the prevention of Francisella tularensis infection. The company has a collaboration with Vitalex Biosciences to advance VXV-01, a dual-antigen vaccine targeting invasive Candida infections. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Halifax, NS, Canada
- Employees
- 7
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.